{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:29:17Z","timestamp":1790731757197,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.autrev.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T17:36:13Z","timestamp":1551720973000},"page":"439-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review"],"prefix":"10.1016","volume":"18","author":[{"given":"Dong Yeon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chei Yun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Yeob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keum Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2019.03.002_bb0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2019.03.002_bb0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","article-title":"IBD immunopathogenesis: a comprehensive review of inflammatory molecules","volume":"16","author":"Park","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0015","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.autrev.2016.07.027","article-title":"Does inflammatory bowel disease coexist with systemic lupus erythematosus?","volume":"15","author":"Shor","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0025","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2015.08.004","article-title":"New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract","volume":"14","author":"Di Sabatino","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2019.03.002_bb0035","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2019.03.002_bb0040","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease","volume":"24","author":"Park","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.sempedsurg.2007.04.002","article-title":"Progress in basic inflammatory bowel disease research","volume":"16","author":"Kugathasan","year":"2007","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.autrev.2019.03.002_bb0050","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.3748\/wjg.v12.i30.4807","article-title":"Etiopathogenesis of inflammatory bowel diseases","volume":"12","author":"Danese","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2019.03.002_bb0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/ajg.2009.190","article-title":"Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review","volume":"104","author":"Hou","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0065","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.3748\/wjg.v20.i29.9675","article-title":"Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease","volume":"20","author":"Renna","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","article-title":"An update on inflammatory bowel disease","volume":"44","author":"Sairenji","year":"2017","journal-title":"Prim Care"},{"key":"10.1016\/j.autrev.2019.03.002_bb0075","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and Management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.autrev.2019.03.002_bb0090","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2019.03.002_bb0095","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2019.03.002_bb0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0105","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0110","doi-asserted-by":"crossref","first-page":"O214","DOI":"10.1111\/codi.13393","article-title":"Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis","volume":"18","author":"Li","year":"2016","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0115","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from cochrane reviews","volume":"19","author":"Feagan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MEG.0b013e328350fc81","article-title":"Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials","volume":"24","author":"Zhu","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0125","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ajg.2011.410","article-title":"Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis","volume":"107","author":"Ford","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0135","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166455","article-title":"Efficacy and safety of Oral Beclomethasone Dipropionate in ulcerative colitis: a systematic review and Meta-analysis","volume":"11","author":"Manguso","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.03.002_bb0145","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0150","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","article-title":"Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis","volume":"10","author":"Komaki","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0160","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.3748\/wjg.v21.i20.6352","article-title":"Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis","volume":"21","author":"Jin","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0165","first-page":"CD007571","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis","author":"Bickston","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0170","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1097\/MD.0000000000000556","article-title":"Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2019.03.002_bb0175","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40259-016-0173-6","article-title":"Adalimumab for moderately to severely active ulcerative colitis: a systematic review and Meta-analysis","volume":"30","author":"Chen","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2019.03.002_bb0185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5009\/gnl15042","article-title":"Efficacy and safety of Adalimumab in moderately to severely active cases of ulcerative colitis: a Meta-analysis of published placebo-controlled trials","volume":"10","author":"Zhang","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.autrev.2019.03.002_bb0190","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0195","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0200","first-page":"CD006790","article-title":"Type I interferons for induction of remission in ulcerative colitis","author":"Seow","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.autrev.2019.03.002_bb0205","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/jcp.25911","article-title":"Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review","volume":"233","author":"Ganji-Arjenaki","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.MIB.0000437495.30052.be","article-title":"Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0215","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/MIB.0000000000000084","article-title":"Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis","volume":"20","author":"Mardini","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0220","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/11632710-000000000-00000","article-title":"Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients","volume":"72","author":"Jonkers","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2019.03.002_bb0225","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3748\/wjg.v16.i15.1908","article-title":"Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis","volume":"16","author":"Sang","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0235","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s10620-007-9760-1","article-title":"A meta-analysis of antibiotic therapy for active ulcerative colitis","volume":"52","author":"Rahimi","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2019.03.002_bb0240","first-page":"CD004722","article-title":"Transdermal nicotine for induction of remission in ulcerative colitis","author":"McGrath","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0245","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0250","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ibd.21374","article-title":"Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses","volume":"17","author":"Turner","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0255","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ibd.22939","article-title":"High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials","volume":"18","author":"Romkens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1751-2980.2012.00576.x","article-title":"Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis","volume":"13","author":"Tong","year":"2012","journal-title":"J Dig Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0265","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cgh.2011.10.043","article-title":"Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis","volume":"10","author":"Ford","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0270","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/ajg.2011.296","article-title":"Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0275","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10620-008-0481-x","article-title":"A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis","volume":"54","author":"Nikfar","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2019.03.002_bb0280","article-title":"Efficacy and safety of Beclomethasone Dipropionate versus 5-Aminosalicylic acid in the treatment of ulcerative colitis: a systematic review and Meta-analysis","volume":"11","author":"Zhao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2019.03.002_bb0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1590\/s0004-2803.201700000-15","article-title":"Efficacy of tacrolimus for induction of remission in patients with moderate-to-severe ulcerative colitis: a systematic review and meta-analysis","volume":"54","author":"Lasa","year":"2017","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0290","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0300","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00228-011-1079-3","article-title":"A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis","volume":"67","author":"Huang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/158352","article-title":"Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"2013","author":"Ji","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.autrev.2019.03.002_bb0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-230X-10-36","article-title":"Moxibustion for ulcerative colitis: a systematic review and meta-analysis","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-013-0440-8","article-title":"Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials","volume":"7","author":"Fujiya","year":"2014","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0320","first-page":"CD007443","article-title":"Probiotics for maintenance of remission in ulcerative colitis","author":"Naidoo","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/apt.13454","article-title":"Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis","volume":"43","author":"Gupta","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0330","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3892\/etm.2012.718","article-title":"Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease","volume":"4","author":"Wang","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2019.03.002_bb0335","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0340","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0345","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Prefontaine","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0350","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0355","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/MIB.0000000000001203","article-title":"Systematic review and meta-analysis: adalimumab monotherapy versus combination therapy with Immunomodulators for induction and maintenance of remission and response in patients with Crohn's disease","volume":"23","author":"Chalhoub","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0360","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","article-title":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0365","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1751-2980.2011.00493.x","article-title":"Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"12","author":"Huang","year":"2011","journal-title":"J Dig Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12325-013-0026-3","article-title":"Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis","volume":"30","author":"Da","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0375","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/MEG.0b013e32834b9544","article-title":"Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease","volume":"23","author":"Lin","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0380","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and Meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0385","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1463-1318.2009.02164.x","article-title":"A meta-analysis of randomized controlled trials comparing antibacterial therapy with placebo in Crohn's disease","volume":"13","author":"Huang","year":"2009","journal-title":"Colorectal Dis"},{"issue":"7","key":"10.1016\/j.autrev.2019.03.002_bb0390","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0395","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/gast.1997.v113.pm9352848","article-title":"Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables","volume":"113","author":"Camm\u00e0","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2019.03.002_bb0400","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00228-014-1702-1","article-title":"Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials","volume":"70","author":"Song","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0405","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s10620-007-0171-0","article-title":"A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease","volume":"53","author":"Rahimi","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2019.03.002_bb0410","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1445-5994.2008.01791.x","article-title":"Meta-analysis: the effect and adverse events of lactobacilli versus placebo in maintenance therapy for Crohn disease","volume":"39","author":"Shen","year":"2009","journal-title":"Intern Med J"},{"issue":"7","key":"10.1016\/j.autrev.2019.03.002_bb0415","article-title":"Anti-tuberculous therapy for maintenance of remission in Crohn's disease","author":"Patton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2019.03.002_bb0420","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1086\/649923","article-title":"Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials","volume":"50","author":"Feller","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2019.03.002_bb0425","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2006.12.012","article-title":"A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease","volume":"28","author":"Rahimi","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2019.03.002_bb0430","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2019.03.002_bb0435","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/1468-2389.00156","article-title":"Fixed effects vs. random effects Meta-analysis models: implications for cumulative research knowledge","volume":"8","author":"Hunter","year":"2000","journal-title":"Int J Sel Assess"},{"key":"10.1016\/j.autrev.2019.03.002_bb0440","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:15:01Z","timestamp":1761599701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1568997219300552"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2019.03.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}